GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
GlobalData on MSN12h
FDA beats EMA to most approved new drugs in 2024The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...
HealthDay on MSN17h
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver CancerFor patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...
The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback